Results 1 to 10 of about 183,958 (171)

Real-world outcome of neoadjuvant therapy with or without pembrolizumab for triple-negative breast cancer [PDF]

Acta Oncologica
Background and purpose: Neoadjuvant therapy (NAT) has become standard therapy for early triple-negative breast cancer (TNBC). The aim of this study was to report real-world outcome of TNBC treated with NAT with or without pembrolizumab and to identify ...
Johanna Mattson, Meeri Maunu, Juho Lähteenmaa, Peeter Karihtala, Suvi Tuohinen, Joonas Laaksolilja, Anders Ståhls, Tuomo Meretoja   +7 more
doaj   +2 more sources

Pembrolizumab [PDF]

Journal for ImmunoTherapy of Cancer, 2015
The development of the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab and its approval in 2011 for the treatment of metastatic melanoma has heralded a new era in immuno-oncology. Subsequently, novel agents against the programmed death receptor 1 (PD-1)/programmed death receptor ligand 1 (PD-L1) axis have shown significant activity in ...
Khoja, Leila, Butler, Marcus O., Kang, S. Peter, Ebbinghaus, Scot, Joshua, Anthony M.   +4 more
openaire   +4 more sources

Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer

Frontiers in Pharmacology, 2021
Background: Pembrolizumab is a guideline-recommended, both first- and second-line treatment option for microsatellite-instability-high (MSI-H)/mismatch repair-deficient (dMMR)advanced colorectal cancer patients.
Tan Chongqing, Tan Chongqing, Li Sini, Zeng Xiaohui, Peng Liubao, Peng Liubao, Peng Ye, Peng Ye, Qin Shuxia, Qin Shuxia, Wang Liting, Wang Liting, Wu Meiyu, Wu Meiyu, Wan Xiaomin, Wan Xiaomin   +15 more
doaj   +1 more source

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma

IJU Case Reports, 2022
Introduction Before the approval of enfortumab vedotin, no standard treatment was available as the salvage treatment for patients with metastatic urothelial carcinoma who had failed second‐line or later pembrolizumab.
Nobutaka Nishimura, Makito Miyake, Takuto Shimizu, Akira Tachibana, Nobumichi Tanaka, Kiyohide Fujimoto   +5 more
doaj   +1 more source

Pembrolizumab (Keytruda) [PDF]

Human Vaccines & Immunotherapeutics, 2016
The programmed cell death protein 1 (PD1) is one of the checkpoints that regulates the immune response. Ligation of PD1 with its ligands PDL1 and PDL2 results in transduction of negative signals to T-cells. PD1 expression is an important mechanism contributing to the exhausted effector T-cell phenotype.
Tse, EWC, Kwok, G, Yau, TCC, Chiu, WYJ, Kwong, YL   +4 more
openaire   +4 more sources

Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials

Frontiers in Pharmacology, 2021
Objective: This network meta-analysis will provide a complete toxicity profile, toxicity profile, and safety ranking of immune checkpoint inhibitors (ICIs) for treatment of advanced non-small cell lung cancer (NSCLC).Methods: We found 12 phase II or III ...
Weidong Zhang, Jingjing Gu, Chunming Bian, Guanhong Huang   +3 more
doaj   +1 more source

Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma

Current Oncology, 2022
Anaplastic thyroid carcinoma (ATC) are highly aggressive malignant tumors with poor overall prognosis despite multimodal therapy. As ATC are extremely rare, no randomized controlled study has been published for metastatic disease.
Laurys Boudin, Jean-Baptiste Morvan, Juliette Thariat, Denis Métivier, Pierre-Yves Marcy, David Delarbre   +5 more
doaj   +1 more source

Two‐year efficacy of SNK01 plus pembrolizumab for non‐small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial

Thoracic Cancer, 2022
Background A previous trial showed that autologous ex‐vivo expanded NK cell (SNK01) treatment combined with pembrolizumab showed better efficacy than pembrolizumab monotherapy in advanced non‐small cell lung cancer (NSCLC). This study was a 2‐year follow‐
Hyung Jun Park, Yong Man Kim, Jae Seob Jung, Wonjun Ji, Jae Cheol Lee, Chang‐Min Choi   +5 more
doaj   +1 more source

Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues

eLife, 2021
Although Pembrolizumab-based immunotherapy has significantly improved lung cancer patient survival, many patients show variable efficacy and resistance development.
Teresa WM Fan, Richard M Higashi, Huan Song, Saeed Daneshmandi, Angela L Mahan, Matthew S Purdom, Therese J Bocklage, Thomas A Pittman, Daheng He, Chi Wang, Andrew N Lane   +10 more
doaj   +1 more source

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial

Liver Cancer, 2021
Introduction: KEYNOTE-240 investigated the efficacy and safety of pembrolizumab plus best supportive care (BSC) in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC).
Masatoshi Kudo, Ho Yeong Lim, Ann-Lii Cheng, Yee Chao, Thomas Yau, Sadahisa Ogasawara, Masayuki Kurosaki, Naoki Morimoto, Kazuyoshi Ohkawa, Tatsuya Yamashita, Kyung-Hun Lee, Erluo Chen, Abby B. Siegel, Baek-Yeol Ryoo   +13 more
doaj   +1 more source